Research Topics
| Shenhong WuSummaryAffiliation: Stony Brook University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysisShenhong Wu
Division of Medical Oncology, Department of Medicine, State University of New York, Stony Brook, NY 11794 9447, USA
Lancet Oncol 9:117-23. 2008..The aim of this study is to gain a better understanding of the overall risk of hypertension in patients with cancer who receive sorafenib...
Bevacizumab increases risk for severe proteinuria in cancer patientsShenhong Wu
Division of Hematology and Oncology, Stony Brook University Medical Center, Stony Brook, New York, USA
J Am Soc Nephrol 21:1381-9. 2010..39). In conclusion, the addition of bevacizumab to chemotherapy significantly increases the risk for high-grade proteinuria and nephrotic syndrome...- Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case reportSanjaykumar Hapani
Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York, USA
J Med Case Reports 4:126. 2010..We report a rare case of eosinophilic pneumonia associated with bleomycin... - Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysisAlyx C Rosen
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 East 53rd Street, New York, New York 10022, USA
J Clin Endocrinol Metab 97:1125-33. 2012..Therefore, we conducted a systematic review and meta-analysis of the literature to determine the incidence and risk of developing a rash... - Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trialsVishal Ranpura
Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
Acta Oncol 49:287-97. 2010..To determine the risk of ATE including cardiac ischemia and stroke, a systematic review and meta-analysis of published randomized controlled trials (RCTs) was performed... 
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysisYuxia Jia
Division of Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York 11794 9447, USA
J Support Oncol 7:211-7. 2009..72 (95% CI: 3.56-6.20) for erlotinib alone and 2.34 (95% CI: 1.64-3.34) for the erlotinib combination. In conclusion, erlotinib is associated with substantial skin toxicity that may be modified by chemotherapy...- Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysisAmna Sher
Department of Medicine, Stony Brook University School of Medicine, NY, USA
Acta Oncol 50:997-1005. 2011..We performed a meta-analysis of randomized controlled trials (RCT) to determine the effect of the anti-VEGF antibody bevacizumab on anemia in cancer patients treated with chemotherapy... - Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse eventsShenhong Wu
Division of Hematology and Oncology, Department of Medicine, Stony Brook University Cancer Center, Stony Brook, New York 11794 9447, USA
Cancer Invest 29:460-71. 2011..Elucidating the molecular basis of these toxicities may lead to clinical benefits by improving patient selection and allowing for the development of effective prevention and management strategies... - Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysisVishal Ranpura
Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
Am J Hypertens 23:460-8. 2010..We performed a systematic review and meta-analysis of published randomized-controlled clinical trials (RCTs) to assess the risk of high-grade hypertension in cancer patients treated with bevacizumab... - Treatment-related mortality with bevacizumab in cancer patients: a meta-analysisVishal Ranpura
Department of Medicine, Stony Brook University Cancer Center, 9447 SUNY, Stony Brook, NY 11794, USA
JAMA 305:487-94. 2011..Currently, the role of bevacizumab in treatment-related mortality is not clear... - Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysisDavid Chu
Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, NY 11794 9447, USA
Clin Genitourin Cancer 7:11-9. 2009..86; 95% CI, 3.1-31.31; P < .001) in comparison with controls. There is a significant risk of developing HFSR in patients with cancer receiving sunitinib. Adequate monitoring and intervention are recommended for reducing the toxicity... - Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysisShobha Rani Nalluri
Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York 11794, USA
JAMA 300:2277-85. 2008..Currently, the role of bevacizumab in venous thromboembolism is controversial... - Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysisSanjaykumar Hapani
Department of Medicine, Division of Hematology and Medical Oncology, Stony Brook University Medical Center, Stony Brook, NY 11794 9447, USA
Oncology 79:27-38. 2010..This study was conducted to determine the overall risk of hemorrhage with bevacizumab by a systematic review and meta-analysis of randomized controlled trials (RCT)... - The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysisYevgeniy Balagula
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Rockefeller Outpatient Pavilion Suite 228, 160 East 53rd Street, New York, NY 10022, USA
Invest New Drugs 30:1773-81. 2012..1-6.2, p < 0.001). Despite sharing the same spectrum of target receptors with sorafenib and sunitinib, pazopanib is associated with an unexpectedly low risk of HFSR. Further investigations are needed to elucidate HFSR pathogenesis... - Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysisDavid Chu
Division of Medical Oncology, Department of Medicine, State University of New York at Stony Brook, Stony Brook, NY 11794, USA
Acta Oncol 47:176-86. 2008..This study was conducted to determine the risk of developing HFSR among patients receiving sorafenib... - Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysisXiao Su
Department of Medicine, AtlantiCare Regional Medical Center, Atlantic City, NJ, USA
Oncology 77:124-33. 2009..Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash... - The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysisBenjamin C Garden
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Am Acad Dermatol 67:400-8. 2012..The overall incidence and risk of nail changes associated with the use of epidermal growth factor receptor inhibitors (EGFRIs) varies widely across the literature... - Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysisSanjaykumar Hapani
Division of Hematology and Medical Oncology, Department of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794 9447, USA
Lancet Oncol 10:559-68. 2009..We did a systematic review and meta-analysis of published randomised controlled trials to assess the overall risk of gastrointestinal perforation associated with bevacizumab treatment... - Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisXiaolei Zhu
Division of Nephrology, SUNY at Stony Brook, NY, USA
Am J Kidney Dis 49:186-93. 2007..We performed a systematic review and meta-analysis of published clinical trials of bevacizumab to quantify the risk of proteinuria and hypertension... - Novel therapies in genitourinary cancer: an updateDavid Chu
Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USA
J Hematol Oncol 1:11. 2008..This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting... - Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificityFrancisco A Chaves
David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester, Rochester, NY 14642, USA
J Immunol Methods 300:74-92. 2005..The results suggest that similar strategies could be used to increase the stability of other unstable class II molecules for in vitro studies...